Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15. doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.

PMID:
23583235
2.

Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.

Flint-Wagner HG, Lisse J, Lohman TG, Going SB, Guido T, Cussler E, Gates D, Yocum DE.

J Clin Rheumatol. 2009 Jun;15(4):165-71. doi: 10.1097/RHU.0b013e318190f95f.

PMID:
19279507
3.

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D.

J Neurosci. 2008 Jul 2;28(27):6787-93. doi: 10.1523/JNEUROSCI.2377-07.2008.

4.

Targeting signaling pathways in multiple myeloma.

Federica C, Antonio P, Guido T, Mario B.

Curr Pharm Biotechnol. 2006 Dec;7(6):407-13. Review.

PMID:
17168656
5.

Depressive symptoms and changes in body weight exert independent and site-specific effects on bone in postmenopausal women exercising for 1 year.

Milliken LA, Wilhelmy J, Martin CJ, Finkenthal N, Cussler E, Metcalfe L, Guido TA, Going SB, Lohman TG.

J Gerontol A Biol Sci Med Sci. 2006 May;61(5):488-94.

PMID:
16720746
6.

Leiomyosarcoma of the broad ligament: a case report and review of literature.

Murialdo R, Usset A, Guido T, Carli F, Boccardo F, Amoroso D.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1226-9. Review.

PMID:
16343220
7.

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M.

Am J Pathol. 2004 Sep;165(3):987-95.

8.

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526.

9.

Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection.

Hui AM, Shi YZ, Li X, Sun L, Guido T, Takayama T, Makuuchi M.

Cancer Lett. 2002 Feb 25;176(2):191-8.

PMID:
11804747
10.

Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, Vasquez N, Wehner N, Johnson-Wood K, Yednock T, Seubert P, Schenk D.

Ann N Y Acad Sci. 2000;920:274-84.

PMID:
11193164
11.

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.

Nat Med. 2000 Aug;6(8):916-9.

PMID:
10932230
12.

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.

Nature. 1999 Jul 8;400(6740):173-7.

PMID:
10408445
13.

Neurodegenerative Alzheimer-like pathology in PDAPP 717V-->F transgenic mice.

Chen KS, Masliah E, Grajeda H, Guido T, Huang J, Khan K, Motter R, Soriano F, Games D.

Prog Brain Res. 1998;117:327-34. Review.

PMID:
9932418
14.

Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients.

Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, Cusimano E, Guido T, Nicolò G, Rosso R.

Breast Cancer Res Treat. 1998 Jan;47(1):41-6.

PMID:
9493974
15.

Breast-cancer in the elderly - detection and treatment modalities in 341 women.

Repetto L, Miglietta L, Costantini M, Queirolo P, Cannata D, Pace M, Gardin G, Guido T, Amoroso D, Campora E, Boccardo F, Rosso R.

Int J Oncol. 1994 Dec;5(6):1399-403.

PMID:
21559727
16.

The impact of received dose intensity on the outcome of advanced ovarian cancer.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al.

Eur J Cancer. 1993;29A(2):181-4.

PMID:
8422279
17.

Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients.

Toma S, Repetto L, Giacchero A, Coialbu T, Costantini M, Addamo GF, Guido T, Rosso R.

J Chemother. 1992 Oct;4(5):321-5.

PMID:
1479423
18.

Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma.

Alama A, Merlo F, Chiara S, Muttini MP, Guido T, Nicolò G, Conte PF, Ragni N.

Eur J Cancer. 1992;28A(6-7):1079-80.

PMID:
1627379
19.

Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.

Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R.

Anticancer Res. 1991 Jul-Aug;11(4):1641-3.

PMID:
1746921
20.

Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.

Queirolo P, Repetto L, Gardin G, Miglietta L, Guido T, Pronzato P, Rosso R.

J Chemother. 1991 Jun;3(3):194-7.

PMID:
1919659
21.

Lonidamine in metastatic breast cancer.

Rosso R, Amoroso D, Gardin G, Miglietta L, Guido T, Pace M, Repetto L, Pronzato P.

Semin Oncol. 1991 Apr;18(2 Suppl 4):62-5. Review.

PMID:
2031200
22.

Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer.

Pronzato P, Bertelli G, Amoroso D, Pennucci C, Gardin G, Guido T, Rosso P.

Chemotherapy. 1991;37(6):449-53.

PMID:
1760945
23.

Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V, Donadio G, Odicino F, Ragni N, Conte PF, et al.

Gynecol Oncol. 1990 Nov;39(2):146-9.

PMID:
2227588
24.

CA-125 monitoring in the management of ovarian cancer.

Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T, Merlini L, Parodi S, Bentivoglio G, Ventrella W, et al.

Anticancer Res. 1990 Sep-Oct;10(5A):1353-9.

PMID:
2241112
25.

Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens.

Repetto L, Chiara S, Pace M, Guido T, Bruzzone M, Oliva C, Murolo C, Conte PF, Rosso R.

Tumori. 1990 Jun 30;76(3):274-7.

PMID:
2195729
26.

Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy.

Murolo C, Costantini S, Foglia G, Guido T, Odicino F, Pace M, Parodi S, Pino G, Ragni N, Repetto L, et al.

J Ultrasound Med. 1989 Aug;8(8):441-3.

PMID:
2668555

Supplemental Content

Support Center